Koers Aoxing Pharmaceutical Company Inc Nyse
Aandelen
US03740A1060
Farmaceutische producten
Omzet 2015 | 25,48 mln. 23,81 mln. | Omzet 2016 | 32,33 mln. 30,21 mln. | Marktkapitalisatie | 49,54 mln. 46,29 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2015 | 5 mln. 4,67 mln. | Nettowinst (verlies) 2016 | 2 mln. 1,87 mln. | EV/omzet 2015 | 5,77 x |
Nettoschuld 2015 | 24,8 mln. 23,18 mln. | Nettoschuld 2016 | 18,56 mln. 17,35 mln. | EV/omzet 2016 | 2,11 x |
K/w-verhouding 2015 |
20,1
x | K/w-verhouding 2016 |
23,2
x | Werknemers | - |
Dividendrendement 2015 * |
-
| Dividendrendement 2016 |
-
| Vrij verhandelbaar | 100% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
David Duarte
CEO | Chief Executive Officer | - | 11-08-23 |
Gui Rong Zhou
CTO | Chief Tech/Sci/R&D Officer | 69 | 01-01-11 |
Peng Jiang
SAM | Sales & Marketing | - | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
David Duarte
CEO | Chief Executive Officer | - | 11-08-23 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+20,61% | 43,18 mld. | |
+20,67% | 22,59 mld. | |
+15,30% | 14,56 mld. | |
+43,35% | 11,5 mld. | |
-8,37% | 6,93 mld. | |
-0,05% | 6,79 mld. | |
-8,87% | 5,73 mld. | |
+10,21% | 5,36 mld. | |
-2,27% | 4,81 mld. |